Larimar Therapeutics, Inc.

About Larimar Therapeutics, Inc.

Larimar Therapeutics is a clinical-stage biotechnology company dedicated to developing treatments for complex rare diseases, with a focus on improving the lives of patients. Their lead product, nomlabofusp, targets Friedreich's ataxia, and they aim to leverage their intracellular delivery platform to address other rare diseases caused by intracellular protein deficiencies.

Products & Services

Nomlabofusp (CTI-1601):A lead product candidate in Phase 2 clinical trials, designed to deliver human frataxin as a potential treatment for Friedreich's ataxia, a rare and progressive genetic disease.

Intracellular Delivery Platform:A proprietary platform intended to deliver proteins and other molecules inside cells, with plans to design fusion proteins for additional rare diseases characterized by intracellular protein deficiencies.

Specialties

Rare Disease Treatment Intracellular Protein Delivery Friedreich's Ataxia Research

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 75000000 MR: - FA: $75 million FAN: 75000000	D: 2026-02-25 FD: 2026-02-25	2 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 100000000 MR: - FA: $100 million FAN: 100000000	D: 2026-02-25 FD: 2026-02-25	6 investors
3	RT: Public Offering T: - FT: Public Offering	A: 69000000 MR: - FA: $69.0 million FAN: 69000000	D: 2025-07-31 FD: 2025-07-31	4 investors
4	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 60000000 MR: - FA: $60.0 million FAN: 60000000	D: 2025-07-29 FD: 2025-07-29	4 investors
5	RT: Public Offering T: - FT: Public Offering	A: 172500000 MR: - FA: approximately $172.5 million FAN: 172500000	D: 2024-02-16 FD: 2024-02-16	4 investors
6	RT: Public Offering T: - FT: Public Offering	A: 150000000 MR: - FA: approximately $150.0 million FAN: 150000000	D: 2024-02-14 FD: 2024-02-14	4 investors

Underwritten Public Offering Latest

2026-02-25

$75.0M

2 investors (Pro only)

Underwritten Public Offering 2026-02-25

$100.0M

Public Offering 2025-07-31

$69.0M

View 5 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

M

Mark Payne, MD

Co-founder and discoverer of CTI-1601

M

Marni Joy Falk

Executive Director of the Mitochondrial Medicine Frontier Program at Children's Hospital of Philadelphia and Professor in the Division of Human Genetics, Department of Pediatrics at University of Pennsylvania Perelman School of Medicine

G

Giovanni Manfredi

Finbar and Marianne Kenny Professor in Clinical and Research Neurology and Professor of Neuroscience at Weill Cornell Medicine

J

Jill Ostrem

MD, Medical Director and Division Chief, Carlin and Ellen Wiegner Endowed Professor of Neurology

C

Carole Ben-Maimon, MD

President and Chief Executive Officer

J

Joseph Truitt

BOARD CHAIR

View 20 more team members with Pro

Unlock Full Team Directory

Recent News